New Life Scientific, Inc. and Telomolecular Corp Announce Strategic Alliance Agreement
New York City, NY, December 05, 2005 --(PR.com)-- New Life Scientific, Inc. (OTCBB:NWLF - News) and Telomolecular Corp, have announced a strategic alliance to develop products that treat aging and age-related disease.
New Life Scientific, Inc a company engaged in developing pharmaceutical products as well as managing PharmaTrials International (PTI), a wholly owned subsidiary of NWLF which operates a Contract Research Organization (CRO) in Kiev, Ukraine. Telomolecular Corp, Biotechnology Company, holder of certain Intellectual Properties of FDA approved gene therapy technologies capable of comprehensive intracellular protein delivery. The move marks an important milestone toward delivering therapeutic large-molecules across human cell membranes in the treatment of presently incurable diseases caused by critical telomere shortening, and in certain trauma injuries. Telomolecular and New Life Scientific hold a variety of possibly synergistic technologies that might eventually enhance market values through collaboration. In particular, New Life Scientific, thru its affiliation IMBG, holds rights to techniques for repairing intracellular DNA damage through stem cell based “DNA exchange” technologies while Telomolecular holds broad field-of-use patents to FDA approved gene therapy technologies capable of comprehensive intracellular protein delivery. Together these concepts might one-day provide more inclusive solutions to human aging and address a variety of disease and trauma processes.
Henry Val, President and Chief Executive Officer of New Life Scientific, Inc., said, "We are enthusiastic about forming a strategic alliance with Telomolecular Corp which we believe will enable us to explore synergistic technology opportunities related to stem cell research."
“Telomolecular looks forward to working with New Life Scientific, Inc. to clinically test and together develop proprietary technologies that will create solutions to human aging," said Matthew Sarad, CEO of Telomolecular Corp.
About Telomolecular.
Telomolecular Corp. was organized with the purpose of engineering a new class of drugs that deliver large-molecule proteins important in the treatment of aging and age-related disease across human cell membranes. The Corporation intends to finance research and development, and commercialize products. By combining new large-molecule delivery technologies with new protein discoveries it may be possible to lengthen chromosomal telomeres in therapeutic ways. Successful therapies based on this tactic may significantly offset, and potentially reverse, many devastating age-related diseases and perhaps address many of the symptoms and signs we recognize as human aging.
About New Life Scientific
New Life Scientific, Inc. recently acquired Novo Life Scientific, the holder of a cooperation agreement with the Institute of Molecular Biology and Genetics of the Ukrainian Academy of Sciences (IMBG). Nova Life Scientific, in conjunction with IMBG, intends to develop and market certain stem cell related products and therapies, and to establish a stem cell bank in the Ukraine. New Life Scientific, Inc. recently acquired Pharma Trials (PTI), a provider of services in the areas of clinical trials, market research and the regulatory approval of products for pharmaceutical companies and Contract Research Organizations. For more information about New Life Scientific please visit its website at http://www.newlifesci.com.
Safe Harbor Statements under the Private Securities Litigation Reform Act of 1965: Those statements contained herein which are not historical are forward-looking statements, and as such, are subject to risks and uncertainties that could cause actual operating results to materially differ from those contained in the forward-looking statements. Such statements include, but are not limited to, certain delays that are beyond the company's control, with respect to market acceptance of new technologies, or product delays in the testing and evaluation of products, and other risks, as detailed in the company's periodic filings with the Securities and Exchange Commission.
Contacts:
Eugene Zabolotsky,
New Life Ssientific, Inc.
732-252-8085
www.newlifesci.com
Investor Relations:
Stan Altschuler / Richard Cooper
Strategic Growth International
212-838-1444
info@sgi-ir.com
###
New Life Scientific, Inc a company engaged in developing pharmaceutical products as well as managing PharmaTrials International (PTI), a wholly owned subsidiary of NWLF which operates a Contract Research Organization (CRO) in Kiev, Ukraine. Telomolecular Corp, Biotechnology Company, holder of certain Intellectual Properties of FDA approved gene therapy technologies capable of comprehensive intracellular protein delivery. The move marks an important milestone toward delivering therapeutic large-molecules across human cell membranes in the treatment of presently incurable diseases caused by critical telomere shortening, and in certain trauma injuries. Telomolecular and New Life Scientific hold a variety of possibly synergistic technologies that might eventually enhance market values through collaboration. In particular, New Life Scientific, thru its affiliation IMBG, holds rights to techniques for repairing intracellular DNA damage through stem cell based “DNA exchange” technologies while Telomolecular holds broad field-of-use patents to FDA approved gene therapy technologies capable of comprehensive intracellular protein delivery. Together these concepts might one-day provide more inclusive solutions to human aging and address a variety of disease and trauma processes.
Henry Val, President and Chief Executive Officer of New Life Scientific, Inc., said, "We are enthusiastic about forming a strategic alliance with Telomolecular Corp which we believe will enable us to explore synergistic technology opportunities related to stem cell research."
“Telomolecular looks forward to working with New Life Scientific, Inc. to clinically test and together develop proprietary technologies that will create solutions to human aging," said Matthew Sarad, CEO of Telomolecular Corp.
About Telomolecular.
Telomolecular Corp. was organized with the purpose of engineering a new class of drugs that deliver large-molecule proteins important in the treatment of aging and age-related disease across human cell membranes. The Corporation intends to finance research and development, and commercialize products. By combining new large-molecule delivery technologies with new protein discoveries it may be possible to lengthen chromosomal telomeres in therapeutic ways. Successful therapies based on this tactic may significantly offset, and potentially reverse, many devastating age-related diseases and perhaps address many of the symptoms and signs we recognize as human aging.
About New Life Scientific
New Life Scientific, Inc. recently acquired Novo Life Scientific, the holder of a cooperation agreement with the Institute of Molecular Biology and Genetics of the Ukrainian Academy of Sciences (IMBG). Nova Life Scientific, in conjunction with IMBG, intends to develop and market certain stem cell related products and therapies, and to establish a stem cell bank in the Ukraine. New Life Scientific, Inc. recently acquired Pharma Trials (PTI), a provider of services in the areas of clinical trials, market research and the regulatory approval of products for pharmaceutical companies and Contract Research Organizations. For more information about New Life Scientific please visit its website at http://www.newlifesci.com.
Safe Harbor Statements under the Private Securities Litigation Reform Act of 1965: Those statements contained herein which are not historical are forward-looking statements, and as such, are subject to risks and uncertainties that could cause actual operating results to materially differ from those contained in the forward-looking statements. Such statements include, but are not limited to, certain delays that are beyond the company's control, with respect to market acceptance of new technologies, or product delays in the testing and evaluation of products, and other risks, as detailed in the company's periodic filings with the Securities and Exchange Commission.
Contacts:
Eugene Zabolotsky,
New Life Ssientific, Inc.
732-252-8085
www.newlifesci.com
Investor Relations:
Stan Altschuler / Richard Cooper
Strategic Growth International
212-838-1444
info@sgi-ir.com
###
Contact
New Life Scientific, Inc.
Eugene Zabolotsky
732.303.7341
www.newlifesci.com
Eugene Zabolotsky
732.303.7341
www.newlifesci.com
Contact
Categories